MedTrace Logo

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

NCT05669833 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2025-10-09

No results posted yet for this study

Summary

The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.

Conditions

Interventions

DRUG

Guselkumab

Guselkumab (GUS) subcutaneous injection

DRUG

Golimumab

Golimumab (GOL) subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • Alexis Ogdie-Beatty, MD, MSCE · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-14
Primary Completion
2026-10-31
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05669833 on ClinicalTrials.gov